Future Prospects of Global Laboratory Proficiency Testing Market

Image
Laboratory Proficiency Testing Market  The global Laboratory Proficiency Testing Market is estimated to be valued at US$ 1.29 billion in 2023 and is expected to exhibit a CAGR of 7.3% over the forecast period 2023 - 2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: Laboratory proficiency testing involves evaluating the performance of laboratories for a given scope of testing through inter-laboratory comparisons. It helps assess the quality and competence of laboratories by determining reproducibility and accuracy of test results. Proficiency testing products are used by laboratories to determine method validity and accuracy, and improve testing processes. Market Key Trends: One of the major trends in the laboratory proficiency testing market is the growing number of accredited medical laboratories. Accreditation assures compliance with ISO 15189 and ISO/IEC 17025 standards, which require participation in proficiency testing programs. Accordi

Muscular Dystrophy Treatment Market will have grown significantly

 Muscular Dystrophy is an X-linked recessive genetic condition that causes muscular deterioration. It can, however, be inherited from parents or created by a novel mutation. Although there are different therapy and medicines to regulate DMD, there is still no cure for the disease.

The introduction of novel medications and therapies, disease-modifying therapies, strong backing from various firms for drug research, and support from patient advocacy groups on the regulatory approval process are all major driving drivers in the worldwide muscular dystrophy treatment market. Furthermore, mutation-specific medicines are expected to be a big breakthrough in the treatment of muscular dystrophy.


https://www.coherentmarketinsights.com/
Muscular Dystrophy Treatment


The FDA's specific recommendation is projected to dominate the worldwide market in North America

North America, Latin America, Europe, Asia-Pacific, and the Middle East and Africa are the regions where the worldwide muscular dystrophy therapy market is segmented. In 2007, the Centers for Disease Control and Prevention estimated that 349 out of 2.37 million males aged 5 to 24 years in the United States had duchenne muscular dystrophy or becker muscular dystrophy. Due to the lack of licenced pharmacological medicines indicated to treat muscular dystrophy, rising prevalence of the condition, and increased research and development for creating effective pharmaceuticals, North America is likely to lead the worldwide muscular dystrophy treatment market. With rising public awareness and increased research activity, Europe is likely to increase its market share during the forecast period.

 

The introduction of effective corticosteroids is expected to increase market demand

Santhera Pharmaceuticals, PTC Therapeutics, BioMarin Pharmaceutical, Sarepta Therapeutics, and Eli Lilly are among the leading companies in the global muscular dystrophy therapy market. Emflaza, an oral corticosteroid approved and launched in 2017, has been demonstrated to be highly successful in helping patients develop strength and walk again. Acceleron Pharma, Capricor Therapeutics, Bristol-Myers Squibb, Lexicon Pharmaceuticals, and Pfizer are among the other providers.

Comments

Popular posts from this blog

Global Disposable Face Mask Market Share

Future Prospects of Global Laboratory Proficiency Testing Market

Global Ophthalmoscopes Market Overview and Impact of Coronavirus (Covid-19) Pandemic